cholest-4-en-3-one | 601-57-0

• 物质功能分类: 天然产物 - 甾体化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholest-4-en-3-one
• 英文别名: Δ⁴-Cholesten-3-on；Δ⁴-Cholestenon；Δ4-Cholestenon；3-Oxo-4-cholesten；Cholest-4-en-3-on；4-Cholesten-3-on；10,13-Dimethyl-17-(6-methylheptan-2-yl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 601-57-0；14615-14-6；23820-66-8；38777-61-6
• 化学式: C₂₇H₄₄O
• mdl: MFCD00277694
• 分子量: 384.646
• InChiKey: NYOXRYYXRWJDKP-UHFFFAOYSA-N

物化性质

• 熔点：
  79-82 °C
• 比旋光度：
  92.5 º (c=2, CHCl3)
• 沸点：
  451.27°C (rough estimate)
• 密度：
  0.9717 (rough estimate)
• 溶解度：
  可溶于氯仿（少量）、甲醇（轻微加热）
• 稳定性/保质期：
  性质与稳定性： 在常温常压下，不会分解产生其他物质。

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• RTECS号：
  FZ7700000
• 海关编码：
  29142900
• 安全说明：
  S22,S24/25
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  一、贮存 应密封于阴凉干燥处保存。

SDS

Name:	4-Cholesten-3-one 99.5+%(tlc) Material Safety Data Sheet
Synonym:	3-Oxo-4-cholesten
CAS:	601-57-0

Section 1 - Chemical Product MSDS Name:4-Cholesten-3-one 99.5+%(tlc) Material Safety Data Sheet
Synonym:3-Oxo-4-cholesten

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
601-57-0	4-CHOLESTEN-3-ONE	99.5+%	210-005-1

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 601-57-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: very slightly yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 79 - 81 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C27H44O
Molecular Weight: 384.64

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 601-57-0: FZ7700000 LD50/LC50:
Not available.
Carcinogenicity:
4-CHOLESTEN-3-ONE - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 601-57-0: No information available.
Canada
CAS# 601-57-0 is listed on Canada's NDSL List.
CAS# 601-57-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 601-57-0 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Cholestenone（4-胆固醇酮）是胆固醇的中间氧化产物，主要在肝脏中代谢。这种化合物在膜中具有很高的流动性，能够影响胆固醇的翻转和外排过程，并可能导致细胞长期功能缺陷。

靶点

Human 内源性代谢物

反应信息

• 作为反应物：
  描述：

  cholest-4-en-3-one 以75的产率得到3-Hydroximinocholest-4-ene
  参考文献：
  名称：

  J. Chem. Soc. Perkin Trans. I 1988, 321

  摘要：

  DOI：
• 作为产物：
  描述：

  cholesterol 以80的产率得到cholest-4-en-3-one
  参考文献：
  名称：

  Anticancer. Res. 2012, 32, 303-310

  摘要：

  DOI：

文献信息

• Lithiation of 3,4-bis(tri-n-butylstannyl)furan: regiospecific synthesis of unsymmetrical 3,4-disubstituted furans
  作者：Yun Yang、Henry N. C. Wong

  DOI：10.1039/c39920001723

  日期：——

  3-(Tri-n-butylstannyl)-4-lithiofuran 2, obtained through tin–lithium exchange from 3,4-bis(tri-n-butylstannyl)furan 1, reacts regiospecifically with various electrophiles to give monosubstituted stannylfurans, which are converted into unsymmetrical 3,4-disubstituted furans utilising Stille's palladium-catalysed coupling reactions.

  3-(三正丁基锡基)-4-锂呋喃2是通过锡-锂交换从3,4-双(三正丁基锡基)呋喃1获得的，它与各种电正体发生区域选择性反应，生成单取代锡呋喃，这些锡呋喃又通过斯蒂尔的钯催化偶联反应转化为非对称的3,4-双取代呋喃。
• LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF
  申请人：Mangelsdorf J. David

  公开号：US20070219173A1

  公开（公告）日：2007-09-20

  Anti-nematode compounds, compositions, and methods for identifying such compounds are disclosed, where the compounds have the formula I: where Q, Q′, R 1 , R 2 , and n are defined herein.

  本文披露了抗线虫化合物、组合物以及鉴定这种化合物的方法，其中化合物的公式为I：其中Q、Q'、R1、R2和n的定义如本文所述。
• Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：EP2587264A1

  公开（公告）日：2013-05-01

  The invention generally relates to the identification metabolites and signatures (panels) of metabolites, which are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. The present invention more particularly relates to an in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and / or basal ganglia.

  本发明一般涉及代谢物和代谢物特征（组）的鉴定，这些代谢物和代谢物特征可作为生物标志物用于临床诊断，特别是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经功能结果，还可用于诊断疾病进展和治疗效果。本发明尤其涉及一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区以及脑损伤风险，并通过鉴定不同脑组织（尤其是海马和/或基底节）的损伤类型和程度来预测预后和神经系统结果。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。
• J. Org. Chem. 1998, 63, 8077-8080
  作者：

  DOI：——

  日期：——